Modified NEMO Protein for X-ray and NMR Structural Studies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying the unbound NEMO protein are limited by the inability to utilize NMR and X-ray techniques, hindering drug discovery efforts aimed at inhibiting the protein-protein interaction between NEMO and IKK, which is crucial for modulating the NF-κB pathway implicated in inflammatory and autoimmune diseases.
Innovation Solution
Modified NEMO proteins and constructs with specific amino acid substitutions and deletions, particularly in residues 44-111, enable X-ray structure determination and NMR-based screening by improving crystal packing and solution behavior, allowing for the identification of compounds binding to NEMO and inhibiting its interaction with IKK.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type NEMO protein is used for structural studies, then the protein maintains its native biological function, but NMR and X-ray techniques cannot be utilized due to poor crystal packing and solution behavior
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions (K47A, Q48A, N51A, T52A, L55A, I56A, Q59A, T61A, Q62A, L63A, Q65A, T67A, Q68A, L69A, Q71A, T72A, Q73A, L74A, R75A, E78A, Q80A, T81A, Q82A, L83A, Q85A, T86A, Q87A, L88A, Q90A, T91A, Q92A, L93A, R94A, C95A, Q96A, T97A, Q98A, L99A, Q101A, T102A, Q103A, L104A, R105A, K106A, E110A) in the NEMO protein sequence. These parameter changes at the molecular level improve crystal packing and solution behavior, enabling the protein to be studied using NMR and X-ray techniques while maintaining its biological function.
2Reliability
If NEMO protein is modified to improve crystal packing and solution behavior, then NMR and X-ray techniques can be utilized, but the protein sequence is altered from wild-type
Solution Approach 1:
The patent introduces specific amino acid substitutions at defined positions in the NEMO protein sequence. These parameter changes are strategically selected to improve crystal packing and solution behavior without disrupting the core functional domains of the protein. The modifications enable NMR and X-ray techniques to be applied while the patent provides comprehensive characterization to confirm functional integrity.
Solution Approach 2:
The patent creates modified NEMO protein variants that serve as surrogate models for structural studies. These modified proteins are optimized for specific analytical techniques (NMR, X-ray) and can be produced and used for their intended purpose without requiring preservation of the exact wild-type sequence, analogous to using optimized proxies for specific measurements.
3Reliability
If wild-type NEMO is used for drug discovery screening, then the screening reflects native biological interactions, but the inability to use NMR and X-ray techniques hinders structure determination and inhibitor validation
Solution Approach 1:
The patent modifies NEMO protein parameters (amino acid sequence) to enable structure determination using NMR and X-ray techniques. The modifications are designed to improve physical properties for analytical techniques while the patent includes validation approaches to ensure the modified proteins remain suitable for drug discovery screening and inhibitor validation.
Solution Approach 2:
The modified NEMO proteins serve as intermediaries that bridge the gap between the need for structural characterization (requiring NMR/X-ray) and the need for biologically relevant screening. The modified proteins enable structure determination and can be used to validate inhibitors, with the understanding that they represent an optimized version for analytical purposes.
Data Source
AI summary
The present disclosure relates to a modified NEMO protein that, inter alia, allows for structural determination of the NEMO protein in the apo-form and in complex with a ligand by NMR or X-ray crystallography. The present disclosure also relates to the use of such modified NEMO proteins to screen and validate inhibitors of the interaction between NEMO and IKKα and/or IKKβ and for structure determination of NEMO in the apo-form and in complex with a ligand, preferably by NMR or X-ray crystallography.